Sign in to CMS Desk. Sign in to CMS Site Manager. The default account is administrator with blank password.
Molecular > NGS

NGS Overview

Molecular methods play an ever-expanding key role in disease diagnosis and classification. Recently, increasing numbers of somatic cancer mutations have been utilized in personalized cancer medicine to determine treatment strategy and patient prognosis.  Importantly, this information is often necessary to match patients with ongoing clinical trials when needed.  Analysis of individual genes or mutations by conventional methodologies will not be efficient enough, or cost-effective enough, to keep pace with increasing clinical needs.  Next-Generation-Sequencing (NGS) provides for efficient and cost-effective analysis of a large panel of somatic cancer genes simultaneously.  This technology can provide a comprehensive clinically-relevant genomic profile specific to each tumor type, utilizing a single test methodology and platform.  CellNetix has designed a custom assay to be used for this purpose.


Our SYMGENE68™ Panel

SYMGENE68™ is a 68-gene NGS panel developed in the CellNetix laboratory which serves effectively for both solid tumors and hematologic malignancies. Genes and the targeted regions within each gene have been carefully selected through an extensive literature review, based on known clinical utility for the major types of cancer. To improve the overall clinical application of the test, approximately 20 additional genes/regions, such as TET2, EZH2, and ASXL1, recently reported in multiple studies to be associated with significant diagnostic or prognostic value, have been included in our panel, in addition to the genes/regions covered by the common commercially available NGS panels offered by other major medical centers and commercial reference labs. Also, in order to increase the detection rate for functionally related gene variants, our panel not only covers the hotspot mutations covered by the common commercially available NGS panels, it also provides coverage of the entire exons harboring those hotspot mutations. Similarly, the entire functional domains for some of the kinase or phosphatase genes, such as PIK3CA, JAK2 or PTPN11, are covered by our panel, which increases the screening power for functional aberrations in these often-targeted regions. For genes without recurrent hotspot regions, such as DNMT3A, EZH2, and PHF6, the entire coding regions of those genes are covered. 


If you are not setup with an electronic interface for NGS testing, please use the below Test Add-on form and fax it to (206) 215-5935 or (866) 721-9696

Test Add-On Form


The CellNetix NGS cancer panel report has been designed to provide clear and detailed genomic information, and to assist in applying that information appropriately to the clinical management of the individual patient.  

  1. Each gene assayed is assigned to one of three categories, based on the variants detected: actionable, applicable, or unknown significance, based on the level of publicly available supporting data regarding available drugs, clinical trials, or prognostic studies.
  2. Then, each gene and each gene variant is addressed separately, with specific information provided regarding the relevant drugs, clinical trials, or prognostic studies. All of the information on each report is individually evaluated by a geneticist and molecular pathologist prior to release.
  3. The genomic data is also correlated with the morphology by our expert pathologists prior to release.  The report is deliberately designed to be immediately accessible and comprehensible.  In the electronic pdf report, accessible online through our web portal, links are embedded to the detailed supporting information available online (including clinical trial sites and literature links).  The entire system is designed to provide the most relevant and direct information possible, in order to provide the timeliest and appropriate clinical care for cancer patients.


Targeted Tumors

  • Thoracic neoplasms
  • Breast and Ovarian carcinomas
  • Colorectal carcinoma
  • Melanoma
  • Gastrointestinal stromal tumor (GIST)
  • Thyroid Carcinoma
  • Urothelial Carcinoma
  • Neurologic malignancy
  • Myelodysplastic syndromes (MDS)
  • Myeloproliferative neoplasms (MPN)
  • Acute Myeloid Leukemia (AML)
  • Acute Lymphoblastic Leukemia


The CellNetix NGS report is designed to be easy for oncologists to read and to quickly assess how the genetic information may help guide treatment.